Cost-benefit analysis of active vaccination campaigns against hepatitis A among daycare centre personnel in Israel

PharmacoEconomics

Volumn 19, Issue 3, 2001, Pages 281-291

  Chodick, Gabriel ^a,b   Lerman, Yehuda ^a,c   Peled, Tamar ^a   Aloni, Hava ^b   Ashkenazi, Shai ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c The National Institute of Occupational Environmental Health   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DAY CARE; EMPLOYEE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRODUCTIVITY; VACCINATION;

EID: 0035082144     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119030-00006     Document Type: Article

References (29)

1. Viral hepatitis
2. Community-wide outbreaks of hepatitis A
3. Clinical manifestations and diagnosis of hepatitis A virus infection
4. Sociodemographic factors and the declining prevalence of anti-hepatitis A antibodies in young adults in Israel: Implications for the new hepatitis A vaccines
5. Prevalence of antibodies against hepatitis A virus among new immigrants in Israel
6. Hepatitis in day care centres: Epidemiology and prevention
7. Infections in child day care centres as they relate to internal medicine
8. Frequency of illness associated with epidemic hepatitis A virus infection in adults
9. Increased risk for hepatitis A among female day nursery workers in Belgium
10. Occupations at increased risk of hepatitis A: A 2-year nationwide historical prospective study
11. Hepatitis A vaccination of child care workers in Victoria: Are recommendations being implemented?
12. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA
13. Is the health ministry official data valid? Hepatitis A as an example
14. Sero prevalence of hepatitis A antibodies among day-care center workers
15. Relapsing hepatitis A: Review of 14 cases and literature survey
16. Critical value of prevalence for vaccination programmes: The case of hepatitis A vaccination in Spain
17. Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence
18. Comparison of viral hepatitis marker test methods based on AABB-CAP survey data
19. Cost-benefit analysis of a nationwide infant immunization program against hepatitis A in an area of intermediate endemicity
20. Should British soldiers be vaccinated against hepatitis A? An economic analysis
21. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travelers
22. An economic analysis of the use of hepatitis A vaccine to control community epidemics
23. Cost-effectiveness of hepatitis A vaccination in healthcare workers
24. Reduction in hepatitis A antibody prevalence among young adults in Israel
25. A large outbreak of hepatitis A in a day-care center
26. Economic evaluation in health care: Is there a role for cost-benefit analysis?